The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
UGT1A1 *28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy.
 
Megan Wong
No Relationships to Disclose
 
Carolyn E. Behrendt
No Relationships to Disclose
 
Wai (Kim) Yu
No Relationships to Disclose
 
Linda D. Bosserman
Leadership - IntegraConnect
Stock and Other Ownership Interests - IntegraConnect; Navigating Cancer
Honoraria - Elsevier
Consulting or Advisory Role - Bio Ascend; MDL Litigation Committe for Taxotere Plantifs; NDP Partners; UpToDate
Patents, Royalties, Other Intellectual Property - UpToDate
 
Sayeh Moazami Lavasani
Consulting or Advisory Role - Puma Biotechnology
Speakers' Bureau - Seagen
 
Niki Patel
Honoraria - OncLive Clinical Congress Consultants; OncLive/MJH Life Sciences
Consulting or Advisory Role - Node.Health
 
Mina S. Sedrak
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Daphne B. Stewart
No Relationships to Disclose
 
James Ross Waisman
No Relationships to Disclose
 
Yuan Yuan
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech; Gilead Sciences; Merck; Pfizer
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
Joanne E. Mortimer
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Puma Biotechnology